Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Patryk Rogaczewski has a total of 13 co-authors. Here are the top co-authors by number of shared publications:

  • Dawid Cyls

    Collegium Medicum, Nicolaus Copernicus University, Bydgoszcz, Poland

    1 shared publication
  • Jacek Kryś

    Collegium Medicum, Nicolaus Copernicus University, Bydgoszcz, Poland

    1 shared publication
  • Jacek Kubica

    Collegium Medicum, Nicolaus Copernicus University, Bydgoszcz, Poland

    1 shared publication
  • Jędrzej Borowczak

    Department of Tumor Pathology and Pathomorphology, Oncology Centre in Bydgoszcz ul. Romanowska, Prof. Franciszek Łukaszczyk Memorial Hospital, Bydgoszcz, Poland

    1 shared publication
  • Kamil Borysewicz

    The Municipal Specialist Hospital in Torun, Torun, Poland

    1 shared publication
  • Klaudyna Grzelakowska

    Collegium Medicum, Nicolaus Copernicus University, Bydgoszcz, Poland

    1 shared publication

Latest Publications

  • Open Access

    PCMT1 as a prognostic marker in breast cancer

    by Patryk Rogaczewski, Michał Janiak, Jędrzej Borowczak, Łukasz Szylberg

    Introduction: Triple-negative breast cancer (TNBC) is one of the most aggressive cancers in women, therefore it is necessary to determine novel prognostic markers to estimate survival and advancement the treatment of the disease. Recently, PCMT1, a protein mediating TNBC immune infiltration, has gained attention as a potential therapeutic target. The aim of the study was to demonstrate the relationship between PCMT1 protein overexpression as a prognostic indicator for patients with TNBC cancer and patient survival. Materials and methods: The study included 64 samples collected from 64 TNBC patients. We used the ImageJ software with the IHC Profiler driver for image analysis. To improve the reliability of the results, we expanded the analysis by including The Cancer Genome Atlas cohort. Results: We observed strong PCMT1 immunoreactivity in breast cancer samples and PCMT1 expression in TNBC was significantly higher than in the control group. Patients with high PCMT1 expression had a significantly lower overall survival rate (60.62% vs. 90.35%, respectively) than patients with low PCMT1 expression. In our study and TCGA groups, PCMT1 expression did not correlate with lymph node involvement and distant metastases but correlated with tumor stage. The results obtained in a larger TCGA group are consistent with those in our research group. Overexpression of PCMT1 was a prognostic marker of shorter survival in patients with TNBC. Conclusions: The overexpression of the PCMT1 protein in triple negative breast cancer significantly correlated with shorter overall survival. The confirmed association could be a potential prognostic biomarker for patients with TNBC.


  • Open Access

    The impact of the COVID-19 pandemic on hospital functioning and mortality among non-COVID-19 patients

    by Patryk Rogaczewski, Dawid Cyls, Michał Kasprzak, Klaudyna Grzelakowska, Jacek Kryś, Jacek Kubica

    Introduction: The pandemic resulted in significant changes in the work organization within medical facilities, mainly hospitals, which were handling the largest numbers of people infected with SARS-CoV-2. The objective of the study was to analyse the impact of the COVID-19 pandemic on the functioning of Antoni Jurasz University Hospital No. 1 in Bydgoszcz as a whole, as well as consider individual departments. Material and methods: The data were acquired from the database of Antoni Jurasz University Hospital No. 1 in Bydgoszcz and included: the average length of hospitalization, number of hospitalizations, and number of deaths, as well as COVID-19 status. Information was collected for each month in the 2020–2021 period with a distinction between specific departments. Results: The highest percentage of COVID-19 hospitalizations as well as the highest percentage of COVID-19 deaths were noted from October 2020 to May/June 2020 and in November and December 2021. Correlations between new monthly COVID-19 cases in Kuyavian-Pomeranian Voivodeship and several parameters (average length of hospitalization, total number of hospitalizations, mortality among non-COVID-19 patients) have been established for selected departments. Conclusions: The analysis of the two years of the COVID-19 pandemic in Antoni Jurasz University Hospital No. 1 in Bydgoszcz, Poland, found in selected departments a significantly increased in-hospital mortality, decreased number of hospitalizations, and decreased length of stay. Departments exhibiting an opposite impact of the pandemic on the average length of hospitalization were identified. Introduction: The pandemic resulted in significant changes in the work organization within medical facilities, mainly hospitals, which were handling the largest numbers of people infected with SARS-CoV-2. The objective of the study was to analyse the impact of the COVID-19 pandemic on the functioning of Antoni Jurasz University Hospital No. 1 in Bydgoszcz as a whole, as well as consider individual departments. Material and methods: The data were acquired from the database of Antoni Jurasz University Hospital No. 1 in Bydgoszcz and included: the average length of hospitalization, number of hospitalizations, and number of deaths, as well as COVID-19 status. Information was collected for each month in the 2020–2021 period with a distinction between specific departments. Results: The highest percentage of COVID-19 hospitalizations as well as the highest percentage of COVID-19 deaths were noted from October 2020 to May/June 2020 and in November and December 2021. Correlations between new monthly COVID-19 cases in Kuyavian-Pomeranian Voivodeship and several parameters (average length of hospitalization, total number of hospitalizations, mortality among non-COVID-19 patients) have been established for selected departments. Conclusions: The analysis of the two years of the COVID-19 pandemic in Antoni Jurasz University Hospital No. 1 in Bydgoszcz, Poland, found in selected departments a significantly increased in-hospital mortality, decreased number of hospitalizations, and decreased length of stay. Departments exhibiting an opposite impact of the pandemic on the average length of hospitalization were identified.


  • Open Access

    Clinical significancy of WNT pathway inhibition in various cancers

    by Patryk Rogaczewski, Michał Janiak, Kamil Borysewicz, Tadeusz Głos, Navid Ahmadi, Łukasz Szylberg

    The tumor microenvironment (TME) plays an important role in the cell cycle. There is a correlation between the Wnt/B–catenin signaling pathway and TME. This article reviews methods of inhibiting Wnt Pathway, a useful process in the treatment of various cancers. Compounds of Wnt/β–Catenin Signaling Pathway, such as TCF–1, have an impact on the differentiation and migration of CD8+ T cells. CCL4 expression is regulated by the beta–catenin protein to recruit CD103+ dendritic cells, which enables CD8+ T cell activation. Inhibition of the Wnt/β–catenin pathway has an impact on ovarian cancer patients’ prognosis, reducing the development of ovarian cancer. Research shows that inhibition of the pathway with the use of the LGK974 inhibitor may boost immunity, especially when applied with a Paclitaxel mix. After treatment, expression of the inhibitory receptors CTLA–4, TIM3, PD–1 on CD8+ T cells decreased. The combination of LGK974 and Paclitaxel can cause the death of tumor cells and significantly inhibit their proliferation. The application of dose–dense Paclitaxel avoids toxicity related to the maximum dose needed to protect the patient's immune system by increasing CD8+ TILs. There are concerns regarding toxicity of the LGK 974, especially for cells dependent on the Wnt/β–catenin pathway to maintain homeostasis. Many Wnt/β–catenin pathway inhibitors are tested against colorectal cancer (CRC) with successful results. These include NSAIDs, porcupine inhibitors, tankyrase inhibitors, Wnt5A inhibitors, and disheveled protein inhibitors.The Wnt/β–catenin pathway, when expressed in Triple Negative Breast Cancer (TNBC), leads to the transition of epithelial to mesenchymal cells. In early clinical development, there are multiple inhibitors (ex. KYA1797K) targeting the Wnt/β–catenin pathway in TNBC cells, which could become a viable anticancer strategy.